Pure Global
NCT06255028

A Study of CNTY-101 in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants With Moderate to Severe Systemic Lupus Erythematosus
Century Therapeutics, Inc.·Phase 1·ClinicalTrials.gov·biologicalNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Systemic Lupus Erythematosus
Drug/Device/Intervention
CNTY-101
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Century Therapeutics, Inc.
Timeline & enrollment
Phase
Phase 1
Start date
Aug 01, 2024
End date
Aug 01, 2028
Enrollment
26 participants
Primary outcome

Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Severity of TEAEs,Percentage of Participants With Dose Limiting Toxicities (DLTs),Recommended Phase 2 Regimen (RP2R) With/Without IL-2

Summary

CALiPSO-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety and efficacy
 of CNTY-101 in participants with moderate to severe systemic lupus erythematosus.

ICD-10 classifications
Systemic lupus erythematosusSystemic lupus erythematosus, unspecifiedLupus erythematosusSystemic lupus erythematosus with organ or system involvementOther forms of systemic lupus erythematosus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06255028
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06255028 through Pure Global AI's free database. This Phase 1 trial is sponsored by Century Therapeutics, Inc. and is currently Not yet recruiting. The study focuses on Systemic Lupus Erythematosus. Target enrollment is 26 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.